Position in MDGL
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$91,089,537
-$7,591,469 QoQ
Shares Held
174,011
+2.7% QoQ
Ownership
0.755%
of shares outstanding
% of Portfolio
0.32%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 36.3614943882858.ToString("F0")%
Shared 2.296981225324836.ToString("F0")%
None 61.341524386389366.ToString("F0")%
Common Shares in MDGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Fiera Capital Corp holds $821,046,758 across 19 Biotechnology names. MDGL ranks #3 (11.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
1,021,970 | $167,112,534 | |
| 2 | ARGX |
Argenx SE
|
217,198 | $158,608,839 | |
| 3 | MDGL |
Madrigal Pharmaceuticals, Inc.
This page
|
174,011 | $91,089,537 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
2,527,076 | $84,202,171 | |
| 5 | XENE |
Xenon Pharmaceuticals Inc.
|
709,529 | $41,259,110 | |
| 6 | TERN |
Terns Pharmaceuticals, Inc.
|
711,326 | $37,501,106 | |
| 7 | IMCR |
Immunocore Holdings plc
|
1,080,099 | $32,564,984 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
135,312 | $27,015,040 |
All Filings in MDGL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $91,089,537 | 174,011 | Shares | Other | 2026-05-12 | |
| 2025-12-31 | $98,681,006 | 169,456 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $58,616,747 | 127,800 | Shares | Other | 2025-11-07 | |
| 2025-06-30 | $39,531,441 | 130,622 | Shares | Other | 2025-08-08 | |
| 2025-03-31 | $43,781,649 | 132,179 | Shares | Other | 2025-05-07 | |
| 2024-12-31 | $33,147,206 | 107,422 | Shares | Other | 2025-01-29 | |
| 2024-09-30 | $23,743,173 | 111,880 | Shares | Sole | 2024-11-01 | |
| 2024-06-30 | $32,334,665 | 115,415 | Shares | Other | 2024-10-31 | |
| No filing history on record for this holder in this stock. | ||||||